Promising trial data for Moderna-Merck skin cancer vaccine sends stock risingByBruce GilPublishedJune 3, 2024
The race for a weight loss pill heats up as a Novo Nordisk competitor releases new trial resultsByBruce GilUpdatedJune 3, 2024
Paramount and Skydance have reached an $8 billion merger deal, report saysByBruce GilUpdatedJune 3, 2024
The FDA may approve psychedelics for treating PTSD. Here's what to knowByBruce GilPublishedJune 3, 2024
Moderna just got FDA approval for its RSV vaccine — only its second product on the marketByBruce GilPublishedMay 31, 2024
Pfizer says its its lung cancer drug Lorbrena could be a $1 billion blockbusterByBruce GilUpdatedMay 31, 2024
Ozempic supply trackers, bird flu vaccines, and Merck's future: Pharma news roundupByBruce GilPublishedMay 31, 2024
Nestle's CEO on the Ozempic era: Consumers' nutritional needs are 'shifting'ByBruce GilPublishedMay 30, 2024
Moderna's mRNA bird flu vaccine trial is close to getting U.S. government fundingByBruce GilUpdatedMay 30, 2024
A burn treatment company's stock has soared amid Israel's war in GazaByBruce GilPublishedMay 29, 2024
Merck is spending $3 billion on an eye drug developer as it braces to lose a key cancer patentByBruce GilPublishedMay 29, 2024
Ozempic and weight loss drug shortages can now be tracked by patientsByBruce GilPublishedMay 29, 2024
Elon Musk's Neuralink was exempt from sharing trial details — but it's doing it anywayByBruce GilPublishedMay 28, 2024
Novo Nordisk says Ozempic is expensive because of America's health care systemByBruce GilPublishedMay 28, 2024
Ozempic can also help with chronic kidney disease, a study funded by Novo Nordisk findsByBruce GilUpdatedMay 24, 2024
A growing number of Americans are skipping medical care because of costByBruce GilPublishedMay 24, 2024
